PHASQ Stock Crashes 99% on Pink Sheets, Bankruptcy Aftermath

PHASQ stock has collapsed to near-zero levels, trading at just $0.000001 USD on the pink sheets (PNK exchange) as of April 21, 2026. The stock has plummeted 99% from its previous close of $0.0001, reflecting the aftermath of PhaseBio Pharmaceuticals’ Chapter 11 bankruptcy filing in October 2022. Once a clinical-stage biopharmaceutical company developing cardiovascular treatments, PHASQ now trades with minimal liquidity and virtually no market capitalization. The company’s lead candidate, bentracimab (PB2452), was in Phase III trials before the reorganization. Today, PHASQ represents one of the market’s most distressed equities, trading on pink sheets with extreme caution warranted for any potential investors.

What Happened to PHASQ Stock Price

PHASQ stock has experienced a catastrophic decline, trading at $0.000001 USD with a 99% loss from its previous close. The stock’s year-high stands at $0.0399, while the year-low matches the current price at $0.000001. Volume remains extremely thin at just 2,500 shares traded, compared to an average volume of 22,310 shares. This dramatic collapse stems directly from PhaseBio’s voluntary Chapter 11 bankruptcy petition filed on October 23, 2022, in the U.S. Bankruptcy Court for the District of Delaware.

The company’s financial metrics paint a grim picture. Earnings per share sit at -$2.14, with a negative price-to-earnings ratio of -0.00000047. The 50-day moving average is $0.000236, while the 200-day average is $0.000666, both far above current trading levels. These technical indicators suggest sustained downward pressure with no recovery momentum.

PhaseBio’s Bankruptcy and Business Collapse

PhaseBio Pharmaceuticals filed for Chapter 11 reorganization in October 2022 after failing to advance its pipeline successfully. The company was a clinical-stage biopharmaceutical firm based in Malvern, Pennsylvania, with approximately 600 full-time employees at its peak. Its lead product candidate was bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor, which was in Phase III clinical trials for patients with uncontrolled bleeding events.

The company also developed PB1046, a vasoactive intestinal peptide analogue for pulmonary arterial hypertension treatment, and PB6440 for resistant hypertension. Despite these promising candidates and a co-development agreement with SFJ Pharmaceuticals X, Ltd., the company could not secure sufficient funding or achieve clinical milestones. The bankruptcy filing effectively ended PhaseBio’s operations as an independent entity, leaving shareholders with nearly worthless equity.

Financial Metrics Show Severe Distress

PHASQ’s financial metrics reveal a company in complete distress. The company reports negative book value per share of -$3.16, indicating liabilities exceed assets. Operating cash flow per share is -$1.61, while free cash flow per share stands at -$1.70, showing the company burns cash without generating revenue. Cash per share is $1.42, but this provides minimal cushion given the company’s obligations.

The current ratio of 1.75 suggests short-term liquidity exists, yet the company’s enterprise value is negative at -$33.96 million. Net profit margin is -12.1%, and return on assets is deeply negative at -0.22%. These metrics confirm PHASQ operates in financial distress with no clear path to profitability or recovery. Track PHASQ on Meyka for real-time updates on this distressed equity.

Market Sentiment and Trading Activity

Trading activity in PHASQ remains minimal, reflecting the stock’s status as a pink sheet security. Daily volume of 2,500 shares represents just 11.2% of the average volume, indicating extremely low liquidity. Bid-ask spreads are likely wide, making it difficult for investors to enter or exit positions at reasonable prices. The stock trades at the same price for both day low and day high at $0.000001, suggesting virtually no intraday price movement.

Liquidation pressure appears absent simply because few investors hold positions worth liquidating. The stock’s presence on pink sheets means it lacks the regulatory oversight and reporting requirements of major exchanges. This environment creates significant risks for any remaining shareholders, as information flow is limited and market-making activity is nonexistent.

Meyka AI’s Assessment of PHASQ

Meyka AI rates PHASQ with a grade of C+, reflecting the stock’s distressed status and bankruptcy aftermath. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of 59.28 out of 100 suggests a HOLD rating, though this applies only to existing shareholders managing positions.

The grade acknowledges that PHASQ operates in the healthcare and biotechnology sectors, which typically show stronger fundamentals. However, PhaseBio’s bankruptcy and near-zero valuation override any sector tailwinds. These grades are not guaranteed, and we are not financial advisors. Investors should conduct thorough due diligence before considering any position in distressed pink sheet securities like PHASQ.

Risks and Considerations for Investors

Investing in PHASQ carries extreme risks that warrant careful consideration. Pink sheet stocks lack the regulatory oversight of major exchanges, creating information asymmetry and potential manipulation risks. The company’s bankruptcy status means equity holders rank last in any liquidation proceedings, potentially receiving nothing. Liquidity is virtually nonexistent, making it nearly impossible to exit positions at fair prices.

Additionally, PHASQ has no analyst coverage, price targets, or upgrade/downgrade consensus available. The stock’s history shows a decline of 99.99% over three years and 99.99998% over ten years, indicating sustained value destruction. Any recovery would require successful emergence from bankruptcy and clinical success with remaining pipeline assets, both highly uncertain outcomes. Investors should treat PHASQ as a speculative, high-risk position suitable only for those who can afford total loss.

Final Thoughts

PHASQ stock represents one of the market’s most distressed equities, trading at $0.000001 USD on pink sheets following PhaseBio’s October 2022 Chapter 11 bankruptcy. The 99% collapse from previous levels reflects the company’s failure to advance its cardiovascular drug pipeline and secure adequate funding. Financial metrics show severe distress with negative book value, negative cash flow, and no clear path to recovery. Trading volume remains minimal at 2,500 shares daily, creating extreme liquidity challenges for any investors. Meyka AI assigns a C+ grade with a HOLD rating, acknowledging the stock’s distressed status. For most investors, PHASQ should be avoided entirely due to bankruptcy risk, lack of analyst coverage, and minimal trading activity. Only those with high risk tolerance and ability to absorb total losses should consider this pink sheet security. The company’s remaining assets and pipeline candidates offer minimal value given the equity’s subordinated position in bankruptcy proceedings.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.